The global epidemic of HIV/AIDS has led to unprecedented attention and commitment from governmements and the international community to improve access to HIV prevention and treatment. The need to better document the effectiveness of HIV prevention and treatment programmes and to do this with the most robust methods possible is widely recognized. Strategic information that monitoring and evaluation (M&E) programmes collect helps to target populations in greatest needs and point to the type of services they should receive.
The aim of this course is to provide participants with practical guidance on how to design and carry out evaluations of HIV prevention and treatment programmes, with a focus on key population groups such as people who use drugs (PWID), female sex workers (FSW) and their clients, and pregnant women.
The course starts with introductory presentations on HIV monitoring and evaluation (M&E) which describe the key concepts such as M&E framework, components of the M&E system and indicators used to assess programme performance. The course will further review using case examples how to monitor and evaluate specific programmes such as HIV prevention in PWID and FSW and their clients and anti-retroviral treatment (ART) programmes. Presentations on evaluation of HIV interventions in PWID FSW and clients will start with an outline of the components of the comprehensive package for HIV prevention in these groups, which are evaluated based on assessments of their availability, coverage, quality and potential impact. Documenting the types of programme components that were provided and their coverage and quality gives information not only on whether the interventions had an impact, but also about how the effect was obtained.
The course will further focus on the assessment of cascade of care and treatment services, from the initial diagnosis of HIV infection, linkage to care and retention in care to measurement of the medium/long term impact of treatment. The term “cascade” refers to the sequence of services needed to achieve desirable impacts and the gradual attrition of coverage of the eligible population at each step of the sequence.
The course will also address the key issues in ART patient monitoring such as cohort reporting, measuring adherence, use of clinical databases and electronic medical records and assessment of HIV drug resistance.
Key Topics of the Course
- Basic principles and concepts of M&E
- Methods used to design monitoring and evaluation studies (routine data collection, cross-sectional studies, cohort studies, quasi-randomized trials, randomized control trials)
- Monitoring and evaluation of ART programmes, including core pre-ART and ART patient monitoring indicators, simple cohort analysis, use of clinical databases and electronic medical records, HIV drug resistance early warning indicators
- Components of comprehensive HIV prevention programmes in PWID, and M&E of HIV prevention in PWID (with case studies)
- Components of comprehensive HIV prevention programmes in FSW and clients of FSW and monitoring and evaluation of HIV prevention (with case studies)
- Analysis of the HIV test–treat–retain cascade
- Indicators used to assess quality of HIV care and treatment
- Using evaluation to identify missed opportunities (services that are lacking, population groups that are not addressed, geographic areas not covered, etc)
The course consists of lectures, exercises and case studies. It is designed to provide participants with practical skills and knowledge in monitoring and evaluation of various components of comprehensive HIV prevention and treatment programmes.
An important part of the course is a group or individual work during which participants will develop protocols for evaluation of HIV programmes or projects. Participants are encouraged to work on a protocol which they can later on use in their countries. The protocols will be presented by participants during the final day of the workshop.
Professionals working on planning, implementation and evaluation of HIV prevention and treatment programmes.
Duration and site
The course takes place in five days.
- Professor George W. Rutherford, MD, Global Health Sciences, University of California, San Francisco, USA
- Associate Professor Ole Kirk, MD, DMSc, Rigshospitalet, University of Copenhagen, HIV Programme, Department of Infectious Diseases, Denmark
- Associate Professor Ivana Bozicevic, MD, DrPH, WHO Collaborating Centre for HIV Surveillance, School of Medicine, University of Zagreb, Croatia